Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Research analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for Bradmer Pharmaceuticals in a research report issued on Wednesday, May 14th. HC Wainwright analyst M. Colonnese now anticipates that the company will earn ($1.20) per share for the quarter, down from their prior forecast of ($0.76). HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($1.41) EPS.
A number of other equities research analysts have also weighed in on the stock. Benchmark raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 31st. BTIG Research upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, April 14th. Finally, Cantor Fitzgerald raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th.
Bradmer Pharmaceuticals Price Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Basic Materials Stocks Investing
- Meta’s 5 Key Pillars for AI Growth—Zuckerberg’s Bold Vision
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Retail Investors Are Betting Big on Rocket Lab—Should You Too?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-plc-logo-1200x675.jpg&h=45&w=95&zc=2){kind=logo}
